Managing chemotherapy side effects: Tumor lysis syndrome

Share this content:

To start this activity click Next at the bottom of this page

Release date: February 15, 2013

Expiration date: February 15, 2015

Estimated time to complete this activity: 45 minutes

This activity is co-provided by the Nurse Practitioner Healthcare Foundation and Haymarket Media Inc.

Statement of need: Tumor lysis syndrome (TLS) is a potentially serious complication of chemotherapy treatment of some cancers. Nursing assessment and management is essential in the prevention and treatment of TLS. Early diagnosis is critical. TLS is managed through identifi cation of high-risk patients, initiation of preventative therapy, early recognition of metabolic and renal complications, and prompt administration of supportive care. Nurses need to know how to assess a patient's risk of TLS and the treatment goals for successful management.

Target audience: This activity has been designed to meet the educational needs of registered nurses and nurse practitioners involved in the management of patients with cancer.

Educational objectives:

• Explain the pathophysiology of tumor lysis syndrome

• Identify two risk factors for developing tumor lysis syndrome

• Describe the treatment options for preventing as well as treating tumor lysis syndrome

Accreditation statement: This continuing nursing education activity is provided by the Nurse Practitioner Healthcare Foundation (NPHF).

NPHF is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Designation statement: Free continuing nursing education credit of 0.75 is available. After reading the article, go to to register, take the posttest, and receive a certificate. A score of 80% is required to pass.

Disclosure of conflicts of interest: The Nurse Practitioner Healthcare Foundation (NPHF) assesses conflict of interest with its instructors, planners, reviewers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by NPHF for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. NPHF is committed to providing its learners with high quality CE activities and related materials that promote improvements or quality in health care.

The faculty: Kevin Curler, PharmD, MBA, BCPS; Lisa A. Thompson, PharmD, BCOP, reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.

The planners, reviewers, and staff: Fiona J. Shannon, MHS, FNP; Phyllis Arn Zimmer, MN, FNP, FAAN; Joyce Pagan; Kristen Childress, DNP, ARNP; Connie Morrison-Hoogstede, MN, ANP, AOCNP, Genean M. Page, RN, OCN, reported no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity.

Disclaimer: The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of or imply endorsement by Nurse Practitioner Healthcare Foundation, American Nurses Credentialing Center, or Haymarket Media Inc.

As this article contains only a review, participants have an implied responsibility to use this newly acquired information while also consulting other appropriate sources of information in order to gain full understanding of the topic.


HOW TO TAKE THE POST-TEST: To obtain CE credit, please click here after reading the article to take the post-test on

Page 1 of 4
You must be a registered member of ONA to post a comment.

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs